Division of Cardiac Surgery, University of Ottawa, Ontario, Canada.
Curr Opin Cardiol. 2010 Mar;25(2):107-13. doi: 10.1097/HCO.0b013e328335fff4.
Transcatheter aortic-valve implantation is a promising new treatment modality for patients with aortic-valve disease, where it may revolutionize the treatment of elderly and high-risk patients.
The two devices currently available, the Edwards Sapien valve and the Medtronic CoreValve system, are presented. With a focus on the CoreValve, we describe the indications, contraindications, procedural technique, cardiologist and heart surgeon team dynamics, and special considerations in patients with concomitant cardiopulmonary disease, peripheral arterial disease, low gradient aortic stenosis, and previous bioprosthetic aortic-valve replacement.
We make a case for judicious team-based adoption of these new technologies and emphasize the need for evidence-based and health economics data. We believe that the above will enable determining the therapeutic niche of these modalities amongst the excellent results of conventional aortic-valve replacement surgery.
经导管主动脉瓣植入术是一种有前途的治疗主动脉瓣疾病的新方法,可能会彻底改变老年和高危患者的治疗方式。
目前有两种可用的设备,爱德华兹思派恩瓣膜和美敦力柯尔瓣膜系统。我们重点介绍了柯尔瓣膜,描述了其适应证、禁忌证、手术技术、心脏病专家和心脏外科医生团队动态,以及伴有心肺疾病、外周动脉疾病、低梯度主动脉瓣狭窄和先前生物瓣主动脉瓣置换的患者的特殊注意事项。
我们提倡明智地采用这些新技术,并强调需要基于证据和健康经济学数据。我们相信,上述内容将有助于确定这些方法在传统主动脉瓣置换手术的卓越结果中的治疗定位。